Hovda T, Sober S, Padrik P, Kruuv-Kao K, Grindedal EM, Vamre TBA, Eikeland E, Hofvind S, Sahlberg KK (2026)
A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score
PLoS One, 21 (7), e0345431
DOI 10.1371/journal.pone.0345431, PubMed 42418475

Padrik P, Tõnisson N, Hovda T, Sahlberg KK, Hovig E, Costa L, Nogueira da Costa G, Feldman I, Sampaio F, Pajusalu S, Ojamaa K, Kallak K, Tihamäe AT, Roht L, Kahre T, Lepland A, Sõber S, Kruuv-Käo K, Tamm M, Varghese J, Evans DG, AnteNOR and BRIGHT Research Consortia (2025)
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Cancers (Basel), 17 (7)
DOI 10.3390/cancers17071056, PubMed 40227593

Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, Lüders T, Fongård M, Nawaz MS, Bosnjak-Olsen T, Buvarp UE, Rosenskiold AKJ, Nguyen NT, Sletbak TT, Seyedzadeh M, Selsås K, Porojnicu AC, Skjerven HK, Hovda T, Sahlberg KK, Torland LA, Lyngra M, Hammarström CL, Hönigsperger EB, Noone JC et al. (2024)
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
Future Oncol, 20 (32), 2457-2466
DOI 10.1080/14796694.2024.2377531, PubMed 39073142